Citizens JMP initiated coverage of Foghorn Therapeutics (FHTX) with an Outperform rating and $9 price target Foghorn is a clinical-stage biotechnology company focused on developing novel therapies for oncology based on targeting key components of the chromatin regulatory system, the analyst tells investors in a research note. The firm says the company is currently trading at cash, which is an opportunity to pick up a “pharma-backed technology company at a bargain.” A leader in chromatin remodeling biology, Foghorn has developed a proprietary Gene Traffic Control platform that enables the determination and validation of genetically determined dependencies, says Citizens.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FHTX:
- Promising Advancements and Strategic Collaborations Position Foghorn Therapeutics as a Strong Buy
- Promising Potential of Foghorn Therapeutics’ FHD-909 Drives Buy Rating Amid Strategic Advances
- Foghorn Therapeutics Reports Progress and Financial Stability
- FHTX Earnings this Week: How Will it Perform?